Search results
Sarepta surges as investors cheer expanded use of gene therapy
Reuters via AOL· 15 hours ago(Reuters) -Sarepta Therapeutics shares surged as much as 40% to a more than three-year high on Friday as an expanded use approval cemented its dominant position in the gene therapy market for ...
Why has the Sarepta stock price (SRPT) gone up more than 35%? | Invezz Why has the Sarepta stock...
Invezz· 17 hours agoSarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in ...
US FDA approves expanded use of Sarepta's Duchenne gene therapy
Reuters· 1 day ago, opens new tab gene therapy for all patients with Duchenne muscular dystrophy aged four and above...
Stock market today: Wall Street coasts to the close of another winning week as Nvidia cools again
Associated Press via Yahoo Finance· 18 hours agoU.S. stocks coasted to the close of their latest winning week on Friday, as Nvidia ’s stock...
S&P 500 Clinches Third Straight Weekly Gain
The Wall Street Journal· 5 hours agoThe S&P 500 ebbed lower Friday, weighed down by a decline in Nvidia shares, but held onto its third consecutive week of gains. The Nasdaq Composite shed...
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Zacks via Yahoo Finance· 11 hours agoFollowing the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation...
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval By Investing.com
Investing.com· 1 day agoThe drug can now be used for patients aged 4 and above who have Duchenne muscular dystrophy (DMD), a...
Stock Market Weekly Review: Nvidia, AI Chip Plays Hit Resistance
Investor's Business Daily· 12 hours agoThe supercomputer will use Nvidia AI processors. Sarepta Therapeutics skyrocketed after the FDA gave...
Sarepta Duchenne gene therapy wins broader use from FDA
BioPharma Dive via Yahoo Finance· 1 day agoThe approval makes Elevidys available to most Duchenne patients at least 4 years of age, despite...
Wall Street coasts to the close of another winning week as Nvidia cools again
Los Angeles Times· 4 hours agoU.S. stocks coasted to the close of their latest winning week on Friday, as Nvidia ’s stock...